Real-World diabetes drug study launches in korea
NCT ID NCT05714683
Summary
This study will monitor the safety and effectiveness of Rybelsus (oral semaglutide) in 600 Korean adults with type 2 diabetes during routine medical care. Participants will take Rybelsus as prescribed by their doctor and be followed for about 26 weeks. The research aims to collect real-world data on side effects and how well the medication controls blood sugar and weight.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.